Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

41.65
-0.3620-0.86%
Post-market: 41.64-0.0125-0.03%16:10 EDT
Volume:18.51K
Turnover:772.61K
Market Cap:207.43M
PE:- -
High:42.15
Open:42.15
Low:41.43
Close:42.01
52wk High:47.00
52wk Low:26.62
Shares:4.98M
Float Shares:4.98M
Volume Ratio:0.54
T/O Rate:0.37%
Dividend:0.02
Dividend Rate:0.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Stock (LLY) in Focus as Company Completes $3.8 Billion AtaiBeckley Purchase

TIPRANKS
·
Sep 11

Eli Lilly Completes Acquisition of AtaiBeckley

Reuters
·
Sep 11

Lilly Completes Acquisition of Ataibeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions

THOMSON REUTERS
·
Sep 11

Legend Biotech : Barclays Cuts Target Price to $74 from $78

THOMSON REUTERS
·
Sep 11

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
Sep 11

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Reuters
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Sep 11

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

GenScript Unit Legend Biotech to Present Updated Long-Term Carvykti Cartitude-2 Data at IMS Meeting

Reuters
·
Sep 10

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Reuters
·
Sep 10

Roche's Drug Pipeline is Deeper than Market Assumes

Dow Jones
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Sep 09

Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented

Reuters
·
Sep 09

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09